

=> d his

(FILE 'HOME' ENTERED AT 10:10:44 ON 01 MAR 2001)

FILE 'MEDLINE' ENTERED AT 10:12:36 ON 01 MAR 2001

L1 4184 S INTERLEUKIN-12 OR IL-12
L2 638 S INTERLEUKIN-15 OR IL-15
L3 393 S INTERLEUKIN-18 OR IL-18
L4 15278 S INTERFERON(A)ALPHA OR IFN-ALPHA
L5 136 S L1 AND L2
L6 217 S L1 AND L3
L7 202 S L1 AND L4
L8 79 S L5 AND PY<1999
L9 64 S L6 AND PY<1999
L10 120 S L7 AND PY<1999

=> s (l8 or l9 or l10) and (lymphoma or cancer or tumor)

82758 LYMPHOMA
17955 LYMPHOMAS
85840 LYMPHOMA
(LYMPHOMA OR LYMPHOMAS)
327602 CANCER
44929 CANCERS
342684 CANCER
(CANCER OR CANCERS)
412884 TUMOR
190578 TUMORS
504414 TUMOR
(TUMOR OR TUMORS)
L11 100 (L8 OR L9 OR L10) AND (LYMPHOMA OR CANCER OR TUMOR)

(FILE 'HOME' ENTERED AT 13:51:37 ON 01 MAR 2001)

FILE 'MEDLINE' ENTERED AT 13:51:49 ON 01 MAR 2001

L1 4184 S INTERLEUKIN-12 OR IL-12
L2 30419 S INTERFERON(A)GAMMA OR IFN-GAMMA
L3 8247 S RETINOID
L4 2295 S L3 AND (TUMOR OR CANCER OR ANTI-TUMOR OR LYMPHOMA)
L5 113 S L3 AND LYMPHOMA
L6 3 S L1 AND L5
L7 17 S L1 AND L3
L8 9 S L7 AND PY<1999
L9 2419 S L2 AND (ANTI-TUMOR OR CANCER OR LYMPHOMA)
L10 208 S L1 AND L9
L11 122 S L10 AND PY<1999
L12 26 S L11 AND COMBIN?
L13 638 S INTERLEUKIN-15 OR IL-15
L14 56 S L13 AND (ANTI-TUMOR OR CANCER OR LYMPHOMA)
L15 17 S L14 AND L1

(FILE 'HOME' ENTERED AT 17:34:02 ON 01 MAR 2001)

FILE 'MEDLINE' ENTERED AT 17:34:13 ON 01 MAR 2001

L1 4184 S INTERLEUKIN-12 OR IL-12
L2 471 S L1 AND (ANTI-TUMOR OR CANCER OR LYMPHOMA)
L3 39 S L2 AND (TREAT? OR THERAP?) AND TOXICITY
L4 22 S L3 AND PY<1999
L5 32 S L2 AND (CYTOKINE OR COMBIN?) AND TOXICITY
L6 20 S L5 AND PY<1999
L7 20 S L6 AND (TREAT? OR THERAP?)
L8 0 S L7 AND REDUC?(W)TOXICITY
L9 11 S L7 AND (INTERFERON(A)GAMMA OR IFN-GAMMA)

Cancer Chemother Pharmacol. 1996, 38 Suppl(3): S16-21.

J Clin Invest. 1995, 96(6): 2578-82.

L8 ANSWER 2 OF 9 MEDLINE

TI Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis.

AU Majewski S; Skopinska M; Marczak M; Szmurlo A; Bollag W; Jablonska S

SO JOURNAL OF INVESTIGATIVE DERMATOLOGY. SYMPOSIUM PROCEEDINGS, *(1996, Apr)* 1 (1) 97-101.

X L8 ANSWER 6 OF 9 MEDLINE

TI Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis.

AU Rook A H; Gottlieb S L; Wolfe J T; Vowels B R; Sood S S; Niu Z; Lessin S R; Fox

SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY, (1997 Jan) 107 Suppl 1: 16-20.

L8 ANSWER 7 OF 9 MEDLINE

TI *Retinoids* synergize with IL-2 to increase interferon-gamma production by peripheral blood mononuclear cells via induction of *IL-12*

AU Fox F E; Cassin M; Gottlieb S; Fakharzadeh S S; Kubin M; Trinchieri G; Cooper K; Rook A H

SO ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1996 Oct 31) 795: 337-40.

L15 ANSWER 12 OF 17 MEDLINE

TI The regulation and biological activity of *interleukin-12*

AU Lee S M; Suen Y; Qian J; Knoppel E; Cairo M S

SO LEUKEMIA AND LYMPHOMA, (1998 May) 29 (5-6) 427-38.

L11 ANSWER 6 OF 100 MEDLINE

TI Response of human intestinal lamina propria T lymphocytes to *interleukin-12* : additive effects of *interleukin-15* and 7.

AU Monteleone G; Parrello T; Luzzza F; Pallone F

SO GUT, *(1998 Nov)* 43 (5) 620-8.

L11 ANSWER 11 OF 100 MEDLINE

TI Role of cytokines in GVL (ESb *lymphoma*) and GVHD after adoptive transfer of allogeneic T lymphocytes in mice.

AU Gresser I; Greco G; Santini S M; Woodrow D; Mecchia M; Parlato S; Logozzi M; Venditti M; Maunoury M T; Belardelli F

SO JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, (1998 Sep), 18 (9) 667-79.

L11 ANSWER 12 OF 100 MEDLINE

TI Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro: synergism between interleukin (*IL*)-12* and *IL-15* or *IL-12* and IL-2.

AU Seidel M G; Freissmuth M; Pehamberger H; Micksche M

SO NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, (1998 Sep) 358 (3) 382-9.

L11 ANSWER 26 OF 100 MEDLINE

TI Use of cellular and cytokine adjuvants in the immunotherapy of *cancer*
AU Salgaller M L; Lodge P A
SO JOURNAL OF SURGICAL ONCOLOGY, *(1998 Jun)* 68 (2) 122-38.

L11 ANSWER 27 OF 100 MEDLINE

TI Enhancement of anti- *tumor* activity of natural killer cells by BALL-1, a B cell
lymphoma line.
AU Hirashima M; Yoshida N; Seki M; Okada H; Takamura S; Mihara Y
SO JAPANESE JOURNAL OF CANCER RESEARCH, *(1998 Apr)* 89 (4) 427-35.

L11 ANSWER 33 OF 100 MEDLINE

TI *Interleukin-12* and *interleukin* - *18* synergistically induce murine *tumor*
regression which involves inhibition of angiogenesis.
AU Coughlin C M; Salhany K E; Wysocka M; Aruga E; Kurzawa H; Chang A E;
Hunter C A; Fox J C; Trinchieri G; Lee W M F
SO JOURNAL OF CLINICAL INVESTIGATION, *(1998 Mar 15)* 101 (6) 1441-52.

L11 ANSWER 36 OF 100 MEDLINE

TI IFN-gamma-inducing factor/ *IL* - *18* administration mediates IFN-gamma- and *IL-
12*-independent antitumor effects.
AU Osaki T; Peron J M; Cai Q; Okamura H; Robbins P D; Kurimoto M; Lotze M T; Tahara H
SO JOURNAL OF IMMUNOLOGY, *(1998 Feb 15)* 160 (4) 1742-9.

L11 ANSWER 37 OF 100 MEDLINE

TI Interferon-gamma-inducing factor elicits antitumor immunity in association
with interferon-gamma production.
AU Tan J; Crucian B E; Chang A E; Aruga E; Aruga A; Dovhey S E; Tanigawa K; Yu H
SO JOURNAL OF IMMUNOTHERAPY, *(1998 Jan)* 21 (1) 48-55.

L11 ANSWER 39 OF 100 MEDLINE

TI *Interleukin-18*, a cytokine which resembles IL-1 structurally and *INTERLEUKIN-12*
functionally but exerts its effect independently of both.
AU Kohno K; Kurimoto M
SO CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, *(1998 Jan)* 86 (1) 11-5.

L11 ANSWER 51 OF 100 MEDLINE

TI Type I interferons enhance production of IFN-gamma by NK cells.
AU Hunter C A; Gabriel K E; Radzanowski T; Neyer L E; Remington J S
SO IMMUNOLOGY LETTERS, *(1997 Oct)* 59 (1) 1-5.

L11 ANSWER 52 OF 100 MEDLINE

TI Interferon-gamma-inducing factor gene transfection into Lewis lung
carcinoma cells reduces tumorigenicity in vivo.
AU Fukumoto H; Nishio M; Nishio K; Heike Y; Arioka H; Kurokawa H; Ishida T;
Fukuoka K; Nomoto T; Ohe Y; Saijo N
SO JAPANESE JOURNAL OF CANCER RESEARCH, *(1997 May)* 88 (5) 501-5.

L11 ANSWER 58 OF 100 MEDLINE

TI A potential role for *interleukin-15* in the regulation of human natural killer cell survival.
AU Carson W E; Fehniger T A; Halder S; Eckhert K; Lindemann M J; Lai C F;
Croce C M; Baumann H; Caligiuri M A

SO JOURNAL OF CLINICAL INVESTIGATION, *(1997 Mar 1)* 99 (5) 937-43.

L11 ANSWER 60 OF 100 MEDLINE

TI Induction by *interleukin-15* of human killer cell activity against lung *cancer* cell lines and its regulatory mechanisms.

AU Takeuchi E; Yanagawa H; Yano S; Haku T; Sone S

SO JAPANESE JOURNAL OF CANCER RESEARCH, *(1996 Dec)* 87 (12) 1251-8.

L11 ANSWER 65 OF 100 MEDLINE

TI Pathogenesis of cutaneous T-cell *lymphoma* : implications for the use of recombinant cytokines and photopheresis.

AU Rook A H; Gottlieb S L; Wolfe J T; Vowels B R; Sood S S; Niu Z; Lessin S R; Fox F E

SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY, *(1997 Jan)* 107 Suppl 1 16-20.

L11 ANSWER 74 OF 100 MEDLINE

TI Antitumor activity of *interleukin-12* in preclinical models.

AU Brunda M J; Luistro L; Rumennik L; Wright R B; Dvornozniak M; Aglione A; Wigginton J M; Wiltrout R H; Hendrzak J A; Palleroni A V

SO CANCER CHEMOTHERAPY AND PHARMACOLOGY, *(1996)* 38 Suppl S16-21.

L11 ANSWER 76 OF 100 MEDLINE

TI Interferon-gamma-dependent expression of inducible nitric oxide synthase,*interleukin-12* , and interferon-gamma-inducing factor in macrophages elicited by allografted *tumor* cells.

AU Sanchez-Bueno A; Verkhusha V; Tanaka Y; Takikawa O; Yoshida R

SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, *(1996 Jul 16)* 224 (2) 555-63.

L11 ANSWER 78 OF 100 MEDLINE

TI Differential utilization of Janus kinase-signal transducer activator of transcription signaling pathways in the stimulation of human natural killer cells by IL-2, *INTERLEUKIN-12* , and *IFN- alpha* .

AU Yu C R; Lin J X; Fink D W; Akira S; Bloom E T; Yamauchi A

SO JOURNAL OF IMMUNOLOGY, *(1996 Jul 1)* 157 (1) 126-37.

L5 ANSWER 5 OF 22 MEDLINE

TI Multiple molecular and cellular changes associated with tumour stasis and regression during *IL* - *12* *therapy* of a murine breast *cancer* model.

AU Dias S; Thomas H; Balkwill F

SO INTERNATIONAL JOURNAL OF CANCER, *(1998 Jan 5)* 75 (1) 151-7.